Core Points - Brompton Split Banc Corp. has completed a treasury offering of preferred shares, raising approximately $38.2 million [1] - The preferred shares were priced at $10.40 each, yielding 6.0% [2] - The fund invests in common shares of the six largest Canadian banks and may hold up to 10% in global financial companies for diversification [3] Fund Performance - The compound annual returns for the preferred shares as of November 30, 2025, are 6.4% for 1 year, 6.4% for 3 years, 5.9% for 5 years, 5.4% for 10 years, and 5.2% since inception [5]

Core Insights - OneMedNet Corporation has demonstrated significant engagement and commercial traction at the RSNA Annual Meeting, indicating strong interest from hospitals, imaging centers, and life sciences innovators in its iRWD™ platform powered by Palantir Foundry [1][2][5] Company Overview - OneMedNet is a leading provider of regulatory-grade, AI-ready Real-World Data (RWD) networks, leveraging over 2,130 healthcare sites to deliver insights that drive innovation in healthcare [6] - The company focuses on providing high-quality, multimodal datasets that support healthcare providers and life sciences organizations in research and product development [5][6] Market Validation - The RSNA 2025 event validated OneMedNet's strategy amid rising demand for regulatory-grade RWD, with healthcare providers expressing a strong interest in utilizing their clinical data assets [2][3] - Life sciences companies and AI developers showed keen interest in the next-generation iRWD™ platform, highlighting its capabilities in providing large-scale, high-fidelity datasets and AI-enabled cohort discovery [4][5] Strategic Partnerships - Healthcare providers are looking for reliable and low-effort ways to engage in healthcare innovation and research, while life sciences organizations require scalable datasets to accelerate product development [5] - OneMedNet's efficient deployment model and opportunities for compliant data sharing were noted as key advantages for potential partners [3][5]

Core Insights - American Rebel Holdings, Inc. has formed a strategic distribution partnership with Ace Distributing, enhancing its presence in South Central Pennsylvania and supporting its "distribution-first" growth strategy [1][2][12] - Ace Distributing, a family-owned wholesaler with over 75 years of experience, will distribute American Rebel Light Beer across 11 counties, leveraging its network of more than 1,400 retail accounts [1][3][9] - The partnership marks American Rebel's fifth top-tier distributor in Pennsylvania, contributing to a rapid expansion in distribution and brand visibility [1][2][8] Company Overview - American Rebel Holdings, Inc. is positioned as "America's Patriotic Brand," focusing on beverages and other patriotic lifestyle products [11][12] - The company emphasizes a values-driven marketing approach, appealing to conservative audiences with its branding and product identity [7][9] Product Details - American Rebel Light Beer is a premium all-natural light lager with a profile of approximately 100 calories, 3.2g carbs, and 4.3% ABV per 12 oz [7][8] - The beer is marketed as "America's Patriotic Beer," aligning with themes of faith, freedom, and patriotism [7][10] Distribution Strategy - The partnership with Ace Distributing is part of a broader strategy to build a national distribution network, with recent additions of multiple distributors in Pennsylvania [2][12] - American Rebel Light Beer has secured distribution in 17 states and aims for further expansion through partnerships with top-tier wholesalers [8][12] Ace Distributing Profile - Ace Distributing has a strong reputation in the industry, recognized for its service and innovative marketing strategies, including community engagement initiatives [9][10] - The company has been nominated for multiple industry awards, reflecting its commitment to quality and excellence in distribution [9][10]

Core Insights - Sanara MedTech Inc. plans to launch OsStic Synthetic Injectable Structural Bio-Adhesive in the U.S. market in Q1 2027, following FDA clearance [1][2] - OsStic has received Breakthrough Device Designation from the FDA, indicating its potential to improve treatment for serious conditions [2] - The product is expected to be the first bone bioadhesive in the U.S. utilizing phosphoserine, α-TCP, and calcium silicate, offering significant advantages over traditional methods [2][3] Product Development and Regulatory Milestones - Sanara and Biomimetic Innovations Ltd (BMI) have achieved significant milestones in product development, clinical trials, and regulatory processes throughout 2025 [3] - The U.S. Patent and Trademark Office granted a patent for OsStic, ensuring protection of its key ingredients and applications until at least 2037 [3][6] - The partnership between Sanara and BMI includes an exclusive license and distribution agreement, enhancing Sanara's market position in orthopedic care [5][6] Market Need and Innovation - OsStic addresses critical limitations in current provisional fixation techniques, providing forty times stronger bonding than traditional calcium phosphate bone cement [2][3] - The product aims to meet the unmet clinical needs in complex joint reconstruction, offering a paradigm shift in treating previously non-repairable fractures [3] - Sanara's commitment to innovation is reflected in its collaboration with BMI to introduce OsStic as a new standard in bone bioadhesives [4]

Core Points - Quorum Information Technologies Inc. has completed a statutory plan of arrangement, resulting in the acquisition of all issued and outstanding common shares at a price of $0.80 per share in cash by 2745122 Alberta Inc., an affiliate of Valsoft Corporation Inc. [1] - The company expects to delist its common shares from the TSX Venture Exchange on or about December 10, 2025, pending final approval [2]. Company Overview - Quorum is a North American SaaS software and services company that provides essential enterprise solutions for automotive dealerships and Original Equipment Manufacturers [3]. - The company offers various products, including a Dealership Management System (DMS), DealerMine CRM, Autovance, Accessible Accessories, and VINN Automotive, which enhance dealership operations and customer satisfaction [5].

Core Insights - KeepZone AI Inc. will make a first installment payment of $200,000 to Scanary Ltd. by December 11, 2025, as part of a $1 million distribution agreement [1][2] - The agreement includes exclusive rights for KeepZone to market and sell Scanary's AI-radar screening systems to stadium operators in Israel for an initial six-month period, which can extend if sales are made [3][4] - This partnership is expected to enhance KeepZone's position in the homeland security sector and create new growth opportunities [4] Financial Details - The total consideration under the distribution agreement is $1 million, with the first installment being $200,000 [2] - The payment is part of a strategic partnership that indicates strong momentum between KeepZone and Scanary [2] Strategic Partnership - The exclusivity granted to KeepZone for marketing Scanary's technology in Israeli stadiums is in addition to existing rights in Canada, Germany, and the UAE [3] - The technology can screen up to 25,000 people per hour without requiring them to stop, which is significant for high-demand venues [3] Company Overview - Jeffs' Brands Ltd. operates as a data-driven e-commerce company on the Amazon Marketplace, focusing on transforming products into market leaders [5]

Core Insights - VisionWave Holdings, Inc. has initiated the patent-application process for its Argus platform, which is a space-enabled, AI-driven counter-unmanned aircraft system (C-UAS) [1][2] - The company aims to secure intellectual property protection for key technologies related to Argus, including its core system architecture and enabling technologies [2][3] - VisionWave plans to follow up with additional patent applications to cover further aspects of the Argus technology stack, enhancing its competitive position in the counter-drone defense market [3][4] Company Strategy - The company has engaged intellectual-property counsel to prepare provisional patent applications focused on various components of the Argus platform, such as the SkyWeave™️ high-frequency AI-driven communications backbone and drone detection methods [2][3] - VisionWave's strategy includes structuring Argus as a multi-patent platform to secure a defensible position around technologies essential for next-generation wide-area counter-drone defense [4] Technology Focus - Key technologies being targeted for patent protection include HF-enabled sensor fusion, multi-layer decision and control logic, and secure key-exchange mechanisms optimized for contested environments [3] - The Argus platform aims to deliver scalable capabilities for the detection, classification, tracking, and defeat of emerging aerial threats, contributing to national security and critical infrastructure protection [5]

Core Insights - Journey Medical Corporation announced successful results from a Phase 1 clinical trial for Emrosi, indicating it can be safely used for up to 16 weeks without significant safety issues [1][2] - Emrosi is FDA-approved for treating inflammatory lesions of rosacea in adults, with a focus on maintaining normal microbiota and avoiding antibiotic resistance [2][5] Company Overview - Journey Medical Corporation is a commercial-stage pharmaceutical company focused on marketing FDA-approved prescription products for dermatological conditions [8] - The company currently markets eight branded FDA-approved prescription drugs aimed at treating common skin conditions [8] Clinical Trial Details - The Phase 1 clinical trial (DFD-29-CD-006) was a multicenter, randomized, double-blind, placebo-controlled study involving 60 healthy adults [2] - The trial achieved all primary microbiological endpoints, showing no significant changes in skin, gastrointestinal, or vaginal microbiota [5] - No significant safety issues were reported during the study, reinforcing the treatment's tolerability [2][5] Rosacea Background - Rosacea is a chronic inflammatory skin condition affecting over 16 million Americans and approximately 415 million people worldwide [3] - The condition significantly impacts patients' self-confidence and social interactions, with many reporting adverse effects on professional life [3]

Core Insights - PharmAla Biotech Holdings Inc. has successfully completed the release testing of its first Australian-made batch of LaNeo™ MDMA 40mg capsules, marking a significant milestone for the company [1] - The company is set to enter an active production schedule for 2026, which includes the development of 20mg capsules and the manufacture of ALA-002 capsules [2] - PharmAla has completed its first delivery of Australian-made product to the Orygen Institute, supporting a Phase 3 Trial for social anxiety in autistic youth, concluding its contract with Orygen [3] Company Overview - PharmAla Biotech Holdings Inc. focuses on the research, development, and manufacturing of MDXX class molecules, including MDMA, and aims to alleviate the global backlog of clinical-grade MDMA for clinical trials and commercial sales [4] - The company is recognized as the only provider of clinical-grade MDMA for patient treatments outside of clinical trials and has completed proof-of-concept research into several drug candidates, including ALA-002 [4] - PharmAla operates under a "regulatory first" principle, emphasizing the importance of strong relationships with regulators in the psychedelics industry [4]

Core Viewpoint - Moleculin Biotech, Inc. has announced agreements for the immediate exercise of existing warrants, which will generate approximately $6.5 million in gross proceeds for the company [1][4]. Group 1: Financial Transactions - The company has entered into agreements for the immediate exercise of warrants to purchase up to 727,969 shares at an exercise price of $6.63 per share and 316,360 shares at an exercise price of $6.3219 per share [1]. - In exchange for the immediate exercise of these warrants, the company will issue new unregistered warrants for an aggregate of up to 2,610,823 shares at an exercise price of $6.63 per share, exercisable upon shareholder approval for a term of five years [3]. - The transaction is expected to close on or about December 11, 2025, subject to customary closing conditions, with net proceeds intended for working capital and general corporate purposes [4]. Group 2: Company Overview - Moleculin Biotech, Inc. is a late-stage pharmaceutical company focused on developing drug candidates for hard-to-treat tumors and viruses [1][7]. - The company's lead program, Annamycin, is designed to avoid multidrug resistance and cardiotoxicity, currently in development for relapsed or refractory acute myeloid leukemia (AML) and soft tissue sarcoma lung metastases [7]. - The company has initiated the MIRACLE Trial, a pivotal Phase 3 trial evaluating Annamycin in combination with cytarabine for the treatment of relapsed or refractory AML, following a successful Phase 1B/2 study [8]. Group 3: Pipeline and Development - Moleculin is also developing WP1066, an immune/transcription modulator targeting brain tumors and other cancers, along with a portfolio of antimetabolites including WP1122 for potential treatment of pathogenic viruses and certain cancer indications [9].